Are you over 18 and want to see adult content?
More Annotations
A complete backup of shoppersgossip.com
Are you over 18 and want to see adult content?
A complete backup of lifetimemovieclub.com
Are you over 18 and want to see adult content?
A complete backup of desar-susten-vacacamposjazmin.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of cowboylifestyle.com
Are you over 18 and want to see adult content?
A complete backup of golaketravis.com
Are you over 18 and want to see adult content?
A complete backup of javaaberto.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of allaboutthejersey.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of milkpoint.com.br
Are you over 18 and want to see adult content?
A complete backup of vestre-slidre-fjellstyre.no
Are you over 18 and want to see adult content?
A complete backup of enabledathleticwear.com
Are you over 18 and want to see adult content?
A complete backup of opensourcebb.com
Are you over 18 and want to see adult content?
Text
patients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
LOW 1-YEAR STROKE RISK AFTER COMMERCIAL WATCHMAN USE The estimated 1-year rate of ischemic stroke after implantation of the Watchman left atrial appendage (LAA) closure device (Boston Scientific) was 1.53% in its first few years of commercial use in the United States, which encompassed a relatively high-risk population of patients with atrial fibrillation (AF), registry data show. ADD-ON CMS PAYMENT SWEETENS SHOCKWAVE CHOICE, BUT COST Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles. At $4,700, the new intravascular lithotripsy system was priced high in the hopes of an NTAP. Some say the math still irks them. The Centers for Medicare & Medicaid Services (CMS) has come through with the anticipated new technology add-on payment (NTAP) for inpatientcoronary
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
FDA APPROVES SHOCKWAVE INTRAVASCULAR LITHOTRIPSY FOR (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially disrupt” calcified plaque and optimizestent placement.
WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
LOW 1-YEAR STROKE RISK AFTER COMMERCIAL WATCHMAN USE The estimated 1-year rate of ischemic stroke after implantation of the Watchman left atrial appendage (LAA) closure device (Boston Scientific) was 1.53% in its first few years of commercial use in the United States, which encompassed a relatively high-risk population of patients with atrial fibrillation (AF), registry data show. ADD-ON CMS PAYMENT SWEETENS SHOCKWAVE CHOICE, BUT COST Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles. At $4,700, the new intravascular lithotripsy system was priced high in the hopes of an NTAP. Some say the math still irks them. The Centers for Medicare & Medicaid Services (CMS) has come through with the anticipated new technology add-on payment (NTAP) for inpatientcoronary
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
FDA APPROVES SHOCKWAVE INTRAVASCULAR LITHOTRIPSY FOR (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially disrupt” calcified plaque and optimizestent placement.
WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers.- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. MYOCARDITIS IN YOUNG PEOPLE AFTER MRNA COVID-19 1 day ago · The US Centers for Disease Control and Prevention (CDC) is reporting a higher-than-expected number of myocarditis cases among young people who received the Pfizer/BioNTech or Moderna mRNA-based COVID-19 vaccines, according to a new report presented yesterday at a meeting of the US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee. CVST RISK FAR LOWER WITH VIRAL-VECTOR VACCINES THAN WITH Cerebral venous sinus thrombosis (CVST), a manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), is much more likely to be observed in patients hospitalized with COVID-19 than in people who have received one of the adenovirus-based COVID-19 vaccines, according to new estimates PUBLISHED 2-YEAR PARTNER 3 DATA SHED NEW LIGHT ON TAVI Published yesterday, 2-year results from the PARTNER 3 trial should help to flesh out the bigger picture of TAVI versus surgery in low-risk patients, but the data can’t yet answer the question of which procedure is the best choice in this group. The results, originally released last year at the virtual 2020 American College ofCardiology (ACC
TYPE A AORTIC DISSECTION TIED TO GREATER MORTALITY IN 1 day ago · While more common among men, type A aortic dissection (TAAD) is associated with substantially higher rates of in-hospital mortality among women, according to new data. Women also tend to present with more advanced disease with intramural hematoma, periaortic hematoma, or complete or partial false DEMOGRAPHIC DISPARITIES IN DISTANCE TO STROKE CARE GREATER 1 day ago · People living in rural areas of the United States not only have to travel farther for certified stroke care than their urban counterparts, but also feel a greater impact from demographic disparities, both of which might have a detrimental impact on patient outcomes, researchers have found. PERIPROCEDURAL MIS ASSOCIATED WITH PCI PROGNOSTICALLY Significant elevations in cardiac troponin (cTn) levels after PCI for chronic coronary syndromes are a significant predictor of adverse clinical outcomes, particularly mortality, and should be routinely measured before and after the procedure to diagnosis type BE ‘MINDFUL’ OF TAVI UNKNOWNS IN YOUNGER PATIENTS, EXPERTS Transcatheter aortic valve implantation is approved in the United States for low-risk patients with severe aortic stenosis, without an age threshold. As the authors of a new review point out, though, much is still unknown about how youth can impact outcomes and future options. Low risk and younger TOBACCO USE STILL RAMPANT AMONG CVD PATIENTS WHO KNOW Despite knowing the ramifications of smoking, more than one in four patients with cardiovascular disease in the United States continue to use tobacco and few enroll in formal cessation programs, according to new data. “These findings indicate ‘NONTRIVIAL’ AMOUNT OF LA THROMBUS FOUND BEFORE AF Left atrial (LA) thrombus is not infrequently found in patients with atrial fibrillation (AF) or flutter who have been taking oral anticoagulation continuously for at least 3 weeks, a meta-analysis suggests. The mean-weighted prevalence was 2.73%, though that number varied widely from 0 to 15.42% TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
ADD-ON CMS PAYMENT SWEETENS SHOCKWAVE CHOICE, BUT COST Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles. At $4,700, the new intravascular lithotripsy system was priced high in the hopes of an NTAP. Some say the math still irks them. The Centers for Medicare & Medicaid Services (CMS) has come through with the anticipated new technology add-on payment (NTAP) for inpatientcoronary
BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
FDA APPROVES SHOCKWAVE INTRAVASCULAR LITHOTRIPSY FOR (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially disrupt” calcified plaque and optimizestent placement.
WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
ADD-ON CMS PAYMENT SWEETENS SHOCKWAVE CHOICE, BUT COST Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles. At $4,700, the new intravascular lithotripsy system was priced high in the hopes of an NTAP. Some say the math still irks them. The Centers for Medicare & Medicaid Services (CMS) has come through with the anticipated new technology add-on payment (NTAP) for inpatientcoronary
BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
FDA APPROVES SHOCKWAVE INTRAVASCULAR LITHOTRIPSY FOR (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially disrupt” calcified plaque and optimizestent placement.
WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. COVID-19: TCTMD’S DAILY DISPATCH FOR JUNE WEEK 1 June 3, 2021. The United States is promising to share excess vaccine doses with other parts of the globe, starting with an initial 25 million earmarked for countries in Latin America and the Caribbean, South and Southeast Asia, and Africa, as well as the Palestinian territories, Gaza, and the West Bank, the New York Times reports. It will also lift the Defense Production Act’s “priorityCONFERENCES
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
KOREAN KAWASAKI CASES DROPPED SHARPLY AMID COVID-19 In the early months of the COVID-19 pandemic, clinicians and immunologists were flummoxed by signs that SARS-CoV-2 appeared to produce a late, systemic inflammatory condition in children that shared several features with Kawasaki disease.Now, in an unexpected corollary, researchers in Korea say that the incidence of true Kawasaki disease has dropped markedly during this same BE ‘MINDFUL’ OF TAVI UNKNOWNS IN YOUNGER PATIENTS, EXPERTS 15 hours ago · Transcatheter aortic valve implantation is approved in the United States for low-risk patients with severe aortic stenosis, without an age threshold. As the authors of a new review point out, though, much is still unknown about how youth can impactoutcomes and
TOBACCO USE STILL RAMPANT AMONG CVD PATIENTS WHO KNOW 13 hours ago · Despite knowing the ramifications of smoking, more than one in four patients with cardiovascular disease in the United States continue to use tobacco and few enroll in formal cessation programs, according to new data. “These findings indicate ROX HEART RADIO: 'GETTING TO KNOW YOU' WITH SHARRONE HAYES 10 hours ago · Rox Heart Radio · Rox Heart Radio: 'Getting to Know You' With Sharrone Hayes Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF isSEARCH - TCTMD.COM
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
‘NONTRIVIAL’ AMOUNT OF LA THROMBUS FOUND BEFORE AF 1 day ago · Left atrial (LA) thrombus is not infrequently found in patients with atrial fibrillation (AF) or flutter who have been taking oral anticoagulation continuously for at least 3 weeks, a meta-analysis suggests. The mean-weighted prevalence was 2.73%, though that number varied widely from 0 to 15.42% EVEN MINIMAL CORONARY CALCIUM ‘NOT BENIGN’ IN YOUNG 1 day ago · Any coronary calcium, no matter how little, found in young patients presenting with chest pain is meaningful in terms of risk prediction and should be addressed, according to Danish research. Clinicians tend to view a low coronary artery calcium (CAC) score FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
FDA: CLASS I RECALL FOR SEVEN MODELS OF MEDTRONIC ICDS AND April 12, 2021. The US Food and Drug Administration is warning physicians about a recall initiated in February for several implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) manufactured by Medtronic: Evera, Viva, Brava, Claria, Amplia, Compia, and Visia. BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018. SOME GOOD NEWS, SOME BAD IN PROPOSED 2021 CMS The proposed rule, which would go into effect January 1, 2021, slashes Medicare payments by 9% for cardiac surgery, 8% for thoracic surgery, 7% for vascular surgery, 7% for general surgery, 7% for neurosurgery, and 6% for ophthalmology compared with 2020 rates. However, it adds telehealth services, including a temporary category of WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
FDA: CLASS I RECALL FOR SEVEN MODELS OF MEDTRONIC ICDS AND April 12, 2021. The US Food and Drug Administration is warning physicians about a recall initiated in February for several implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) manufactured by Medtronic: Evera, Viva, Brava, Claria, Amplia, Compia, and Visia. BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018. SOME GOOD NEWS, SOME BAD IN PROPOSED 2021 CMS The proposed rule, which would go into effect January 1, 2021, slashes Medicare payments by 9% for cardiac surgery, 8% for thoracic surgery, 7% for vascular surgery, 7% for general surgery, 7% for neurosurgery, and 6% for ophthalmology compared with 2020 rates. However, it adds telehealth services, including a temporary category of WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers.TCTMD - TCTMD.COM
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
COVID-19: TCTMD’S DAILY DISPATCH FOR JUNE WEEK 1 June 3, 2021. The United States is promising to share excess vaccine doses with other parts of the globe, starting with an initial 25 million earmarked for countries in Latin America and the Caribbean, South and Southeast Asia, and Africa, as well as the Palestinian territories, Gaza, and the West Bank, the New York Times reports. It will also lift the Defense Production Act’s “priority BLOOD CLOTS AFTER COVID-19 VACCINATION LINKED TO IMMUNE The same applies to the ChAdOx1 nCoV-19 vaccine. “The risk of getting this complication is so low compared to the risks of all kinds of bad things that can happen from COVID, including blood clots, stroke, heart attacks, deep vein thrombosis, and so on,” he said. “I think the benefits of these vaccines greatly outweigh therisk.”.
BE ‘MINDFUL’ OF TAVI UNKNOWNS IN YOUNGER PATIENTS, EXPERTS 8 hours ago · Transcatheter aortic valve implantation is approved in the United States for low-risk patients with severe aortic stenosis, without an age threshold. As the authors of a new review point out, though, much is still unknown about how youth can impact outcomes and KOREAN KAWASAKI CASES DROPPED SHARPLY AMID COVID-19 In the early months of the COVID-19 pandemic, clinicians and immunologists were flummoxed by signs that SARS-CoV-2 appeared to produce a late, systemic inflammatory condition in children that shared several features with Kawasaki disease.Now, in an unexpected corollary, researchers in Korea say that the incidence of true Kawasaki disease has dropped markedly during this same REACTION TO PAPER ON AFFIRMATIVE ACTION IN CARDIOLOGY MAY 11 hours ago · A paper published last year that argued against affirmative action in medicine, and was subsequently retracted, may have had the unintended effect of broadening discussions around inclusivity and underrepresentation of minorities in clinical andacademic circles, a
HIGH ISCHEMIC RISK AND BLEEDING RISK: A DELICATE BALANCE 1 day ago · More than half of patients who underwent PCI at a single center in China met criteria for being at high risk for subsequent ischemic events, and the presence of these high-ischemic-risk (HIR) characteristics was indeed associated with worse clinical outcomes, a new real-world analysis confirms. ‘NONTRIVIAL’ AMOUNT OF LA THROMBUS FOUND BEFORE AF 1 day ago · Left atrial (LA) thrombus is not infrequently found in patients with atrial fibrillation (AF) or flutter who have been taking oral anticoagulation continuously for at least 3 weeks, a meta-analysis suggests. The mean-weighted prevalence was 2.73%, though that number varied widely from 0 to 15.42% EVEN MINIMAL CORONARY CALCIUM ‘NOT BENIGN’ IN YOUNG 1 day ago · Any coronary calcium, no matter how little, found in young patients presenting with chest pain is meaningful in terms of risk prediction and should be addressed, according to Danish research. Clinicians tend to view a low coronary artery calcium (CAC) score A NEW BIOMARKER TO DIAGNOSE ACUTE MYOCARDITIS? A novel microRNA measured in plasma, first discovered in mice and then isolated in humans for the first time, eventually might provide a simpler way to diagnose acute myocarditis, a preliminary study suggests. Expressed by type 17 helper T (Th17) lymphocytes, levels of TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
DEATHS AFTER ABLATION OF ATRIAL FIBRILLATION ‘CONCERNING (UPDATED) The risk of death following catheter ablation for atrial fibrillation is higher than rates observed in randomized controlled trials, with the majority of deaths occurring not during the procedure but rather in the 30 days after discharge, according to a large analysis of real-world data. The early mortality rate, defined as death during the initial admission or 30-day readmission TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018. NEW EUROPEAN HYPERTENSION GUIDELINES NOT IN HARMONY WITH The European document establishes target ranges, advising a systolic target of 130 mm Hg, but not lower than 120 mm Hg, for most adults younger than 65. For adults 65 and older, regardless of comorbidities, the treatment target range is the same as the one in younger patients with chronic kidney disease: less than 140 mm Hg, but no lower than WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. LOADING DOSE SMOOTHS SWITCH FROM TICAGRELOR TO CLOPIDOGREL March 19, 2018. ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the SWAP-4 studyshould
TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
DEATHS AFTER ABLATION OF ATRIAL FIBRILLATION ‘CONCERNING (UPDATED) The risk of death following catheter ablation for atrial fibrillation is higher than rates observed in randomized controlled trials, with the majority of deaths occurring not during the procedure but rather in the 30 days after discharge, according to a large analysis of real-world data. The early mortality rate, defined as death during the initial admission or 30-day readmission TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018. NEW EUROPEAN HYPERTENSION GUIDELINES NOT IN HARMONY WITH The European document establishes target ranges, advising a systolic target of 130 mm Hg, but not lower than 120 mm Hg, for most adults younger than 65. For adults 65 and older, regardless of comorbidities, the treatment target range is the same as the one in younger patients with chronic kidney disease: less than 140 mm Hg, but no lower than WHEN CHOSEN WISELY, 90-YEAR-OLDS DO WELL AFTER TAVR When Chosen Wisely, 90-Year-Olds Do Well After TAVR. By Caitlin E. Cox. April 02, 2016. Chicago, IL—New analysis of data from the PARTNER 1 randomized and registry cohorts shows that patients aged 90 years or older who undergo TAVR do not have any increase in mortality or major cardiovascular events compared with their younger peers. LOADING DOSE SMOOTHS SWITCH FROM TICAGRELOR TO CLOPIDOGREL March 19, 2018. ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the SWAP-4 studyshould
- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. COVID-19: TCTMD’S DAILY DISPATCH FOR JUNE WEEK 1 June 3, 2021. The United States is promising to share excess vaccine doses with other parts of the globe, starting with an initial 25 million earmarked for countries in Latin America and the Caribbean, South and Southeast Asia, and Africa, as well as the Palestinian territories, Gaza, and the West Bank, the New York Times reports. It will also lift the Defense Production Act’s “priority KOREAN KAWASAKI CASES DROPPED SHARPLY AMID COVID-19 1 day ago · In the early months of the COVID-19 pandemic, clinicians and immunologists were flummoxed by signs that SARS-CoV-2 appeared to produce a late, systemic inflammatory condition in children that shared several features with Kawasaki disease.Now, in an unexpected corollary, researchers in Korea say that the incidence of true Kawasaki disease has dropped markedly during this same HIGH ISCHEMIC RISK AND BLEEDING RISK: A DELICATE BALANCE 7 hours ago · More than half of patients who underwent PCI at a single center in China met criteria for being at high risk for subsequent ischemic events, and the presence of these high-ischemic-risk (HIR) characteristics was indeed associated with worse clinical outcomes, a new real-world analysis confirms.SLIDES | TCTMD.COM
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
‘NONTRIVIAL’ AMOUNT OF LA THROMBUS FOUND BEFORE AF 11 hours ago · Left atrial (LA) thrombus is not infrequently found in patients with atrial fibrillation (AF) or flutter who have been taking oral anticoagulation continuously for at least 3 weeks, a meta-analysis suggests. The mean-weighted prevalence was 2.73%, though that number varied widely from 0 to 15.42% CENTRAL AND EASTERN EUROPE FAILING TO ACHIEVE LDL 1 day ago · There are substantial gaps in the treatment of LDL-cholesterol levels among primary and secondary prevention patients throughout Europe, a new analysis shows. But the gaps are particularly large in central and eastern European countries. In the EVEN MINIMAL CORONARY CALCIUM ‘NOT BENIGN’ IN YOUNG 13 hours ago · Any coronary calcium, no matter how little, found in young patients presenting with chest pain is meaningful in terms of risk prediction and should be addressed, according to Danish research. Clinicians tend to view a low coronary artery calcium (CAC) score TRIALS SUGGEST NEED FOR PROLONGED AF MONITORING IN MORE Taking a longer look for subclinical atrial fibrillation (AF) after a stroke will turn up more cases compared with shorter-term monitoring—that’s not surprising. But results from two trials published in the June 1, 2021, issue of JAMA suggest that it might be worth doing prolonged monitoring A NEW BIOMARKER TO DIAGNOSE ACUTE MYOCARDITIS? A novel microRNA measured in plasma, first discovered in mice and then isolated in humans for the first time, eventually might provide a simpler way to diagnose acute myocarditis, a preliminary study suggests. Expressed by type 17 helper T (Th17) lymphocytes, levels of TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
DEATHS AFTER ABLATION OF ATRIAL FIBRILLATION ‘CONCERNING (UPDATED) The risk of death following catheter ablation for atrial fibrillation is higher than rates observed in randomized controlled trials, with the majority of deaths occurring not during the procedure but rather in the 30 days after discharge, according to a large analysis of real-world data. The early mortality rate, defined as death during the initial admission or 30-day readmission TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018. TCTMD - TCTMD.COMNEWSCONFERENCESSLIDES & MORETOPICSVIDEOSREGISTER TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
FDA: MEDTRONIC STOPS PRODUCTION AND DISTRIBUTION OF By L.A. McKeown. June 03, 2021. In a letter to healthcare providers, the US Food and Drug Administration said today that Medtronic has ceased the sale and distribution of its HeartWare ventricular assist device (HVAD) system. The action was taken due to a higher frequency of neurological adverse events and death compared with othercommercially
SCAI EXPERTS UPDATE TRANSRADIAL GUIDANCE January 03, 2020. It’s time to revisit “best practices” for transradial procedures, say experts from the Society for Cardiovascular Angiography and Interventions (SCAI). With 6 years of additional data to inform their advice, a newly updated consensus statement recommends the use of ultrasound to guide vascular access,suggests the ulnar
BLOOD PRESSURE INSIGHTS IN COVID-19: WATCH FOR DROPS AND September 10, 2020. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meetingsuggests
STROKESTOP: SMALL CLINICAL BENEFIT SEEN WITH SYSTEMATIC AF A population-based screening program for atrial fibrillation (AF) improved clinical outcomes in 75- and 76-year-olds living in two regions of Sweden, the randomized STROKESTOP shows. Over more than 5 years of follow-up, risk of the combined primary endpoint of ischemic stroke, systemic thromboembolism, all-cause mortality, hemorrhagicstroke
DEATHS AFTER ABLATION OF ATRIAL FIBRILLATION ‘CONCERNING (UPDATED) The risk of death following catheter ablation for atrial fibrillation is higher than rates observed in randomized controlled trials, with the majority of deaths occurring not during the procedure but rather in the 30 days after discharge, according to a large analysis of real-world data. The early mortality rate, defined as death during the initial admission or 30-day readmission TCT 2018 | TCTMD.COM LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presenter: Mitchell W. Krucoff. September 22, 2018. Presentation TCT 2018.- TCTMD.COM
TCTMD is pleased to offer its members an enhanced educational experience with TCTMD Prime, Gold, and Platinum premium membership levels. Please review the following membership options and choose the one that is right for you. KOREAN KAWASAKI CASES DROPPED SHARPLY AMID COVID-19 1 day ago · In the early months of the COVID-19 pandemic, clinicians and immunologists were flummoxed by signs that SARS-CoV-2 appeared to produce a late, systemic inflammatory condition in children that shared several features with Kawasaki disease.Now, in an unexpected corollary, researchers in Korea say that the incidence of true Kawasaki disease has dropped markedly during this same COVID-19: TCTMD’S DAILY DISPATCH FOR JUNE WEEK 1 June 3, 2021. The United States is promising to share excess vaccine doses with other parts of the globe, starting with an initial 25 million earmarked for countries in Latin America and the Caribbean, South and Southeast Asia, and Africa, as well as the Palestinian territories, Gaza, and the West Bank, the New York Times reports. It will also lift the Defense Production Act’s “prioritySLIDES | TCTMD.COM
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of theirpatients’ lives.
VALVE DISEASE PLUS COVID-19 OFTEN A LETHAL COMBINATION Swift treatment—with caveats—cuts the risk. Four in 10 patients who contract COVID-19 on top of valvular heart disease (VHD) die within 30 days of hospital admission, according to multicenter registry data. That mortality rate, researchers say, is perhaps enough to justify pursuing valve repair or replacement even in the context ofSARS-CoV-2.
LEFT MAIN BIFURCATION STENTING: WHAT’S THE BEST APPROACHCLICK TOVIEW
1 day ago · Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality CENTRAL AND EASTERN EUROPE FAILING TO ACHIEVE LDL 1 day ago · There are substantial gaps in the treatment of LDL-cholesterol levels among primary and secondary prevention patients throughout Europe, a new analysis shows. But the gaps are particularly large in central and eastern European countries. In the TRIALS SUGGEST NEED FOR PROLONGED AF MONITORING IN MORE Taking a longer look for subclinical atrial fibrillation (AF) after a stroke will turn up more cases compared with shorter-term monitoring—that’s not surprising. But results from two trials published in the June 1, 2021, issue of JAMA suggest that it might be worth doing prolonged monitoring A NEW BIOMARKER TO DIAGNOSE ACUTE MYOCARDITIS? A novel microRNA measured in plasma, first discovered in mice and then isolated in humans for the first time, eventually might provide a simpler way to diagnose acute myocarditis, a preliminary study suggests. Expressed by type 17 helper T (Th17) lymphocytes, levels of STENTING FOR AORTIC COARCTATION CAN HAVE LATE Young patients who receive stents to treat coarctation of the aorta see good hemodynamic results over the long term, combined data from the COAST and COAST II trials show, but late follow-up from these two studies also suggests that their complication risk doesn’t remain static—stent fractures, reinterventions, and aortic aneurysms can arise 4 to 5 years after treatment. Skip to main contentADVERTISEMENT
TOP USER MENU
* Register
* " class="is-active">LoginMAIN NAVIGATION
* News
* Conferences
* Slides & More
* Slides
* CME
* Live Cases
* Member Cases
* Podcasts
* Cath Lab Forum
* Manuscripts
* Topics
* Clinical Cardiology* Coronary
* Endovascular
* Heart Failure
* Heart Rhythm
* Imaging & Physiology* Policy & Practice
* Structural Heart
* Videos
Fellows Forum
News • Interventional News • Interventional IN CAROTID RCTS, OUTCOMES IMPROVED OVER TIME FOR CEA BUT NOT CAS:META-ANALYSIS
But an outside source questioned the decision to lump CREST together with EVA-3S, SPACE, and ICSS.By Caitlin E. Cox
August 09, 2019
News
ECHO OVERUSE IN HEART FAILURE STABILIZES IN THE WAKE OF ONTARIO APPROPRIATENESS EFFORTS Accreditation programs, appropriate use criteria, and physician leaders who lead the charge can effect meaningful change, the studysuggests.
By Michael O'RiordanAugust 09, 2019
News
LANCET EDITORS REJECT ‘MANELS’ WITH NEW POLICY With their new diversity pledge, the medical publishing group hopes to increase the representation of women in medicine.By Yael L. Maxwell
August 09, 2019
SLIDES
See all
Presentation
CHIP Seattle 2019
COMPLEX CORONARY INTERVENTION PROGRAMS DEDICATION FOR ADVANCEMENT Presenter: David E. KandzariAugust 02, 2019
Presentation
CHIP Seattle 2019
MANAGING CORONARY ARTERY DISSECTION WITH NO WIRE ACCESS Presenter: Robert F. RileyAugust 02, 2019
Presentation
CHIP Seattle 2019
UNEXPECTED HEMODYNAMIC COLLAPSE DURING PCI Presenter: Craig A. ThompsonAugust 02, 2019
ADVERTISEMENT
NEWS
See all
News • Interventional CTO PCI CONSENSUS DOCUMENT AIMS FOR QUALITY, CONSISTENCY BUT ACKNOWLEDGES DATA GAPSBy Yael L. Maxwell
August 08, 2019
News
HIGHER MORTALITY WITH OFF-PUMP CABG: EXCEL ANALYSIS By Michael O'RiordanAugust 08, 2019
Feature
ANTICOAGULATION ON DEMAND? THE PILL-IN-THE-POCKET APPROACH TO A-FIBTREATMENT
The strategy aims to leverage advancements in pharmacology and technology to fundamentally change how A-fib is managed.Todd Neale
June 25, 2019
Feature • Interventional STRUCTURAL HEART HYPE: AS FELLOWSHIP PROGRAMS MUSHROOM, WHO’S KEEPING TABS ON QUALITY AND NUMBERS? The allure of TAVR and LAA closure sways many trainees to sign on for an extra year, but programs are varied and jobs are few.Yael L. Maxwell
August 02, 2019
News • Interventional EARLIER CARE, MORE DATA NEEDED TO INCREASE TREATMENT SUCCESS IN TRICUSPID REGURGITATIONBy Yael L. Maxwell
August 07, 2019
News
FDA GIVES EAGERLY AWAITED UPDATE ON MORTALITY WITH PACLITAXEL-COATEDDEVICES IN PAD
By Todd Neale
August 07, 2019
News
SMARTPHONE SELFIE MAY REVEAL BP LEVELS, EARLY RESULTS SUGGESTBy Todd Neale
August 07, 2019
News • Interventional TAVR BLEEDS STAND APART FROM PCI-RELATED EVENTSBy Caitlin E. Cox
August 06, 2019
News
NIGHTTIME, 24-HOUR BP READINGS HAVE STRONGEST LINK TO POOR OUTCOMESBy Todd Neale
August 06, 2019
ADVERTISEMENT
VIDEOS
See all
Video Player is loading.Play VideoPlay
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVESeek to live, currently playing liveLIVE Remaining Time -0:00Playback Rate
1x
Chapters
* Chapters
Descriptions
* descriptions off, selectedCaptions
* captions settings, opens captions settings dialog * captions off, selectedAudio Track
Fullscreen
This is a modal window. Beginning of dialog window. Escape will cancel and close the window. TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque Font Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps Reset restore all settings to the default valuesDoneClose Modal Dialog End of dialog window.Close Modal Dialog
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.On Record
ON RECORD: DOES DEVICE REGULATION NEED MORE CROSSTALK TO IMPROVEACCESS, SAFETY?
Conference Wrap-Up
CONFERENCE CATCH-UP WITH DAVIDE CAPODANNO AT EUROPCR 2019June 7, 2019
Topical Discussion
Sponsored
STOPDAPT 2 – GLOBAL EXPERTS DISCUSS THE RESULTS AND IMPLICATIONS OF LANDMARK SHORT DAPT STUDYJune 6, 2019
Conference Wrap-Up
SCAI 2019 CONFERENCE CATCH-UP WITH YAEL L. MAXWELLJune 5, 2019
Topical Discussion
TAVR IN 2019: APPROPRIATE METRICS FOR SUCCESSMarch 21, 2019
PODCASTS
See all
Heart Sounds
TOP STORIES IN CARDIOLOGY: JULY 2019 Topics this month range from chest-pain triage, to valsartan-related cancers, to ischemia as a predictor of CV outcomes.Taking It To Heart
EPISODE 4: MITRAL ANNULAR CALCIFICATION In this episode, we provide an overview of mitral annular calcification (MAC), with a focus on anatomy, surgical and transcatheter therapy and challenges in treatment.Rox Heart Radio
MITRAL VALVE HOT TOPICS Roxana Mehran delves into mitral valve hot topics with Suzanne Arnoldand Saibal Kar.
Test your interventional knowledge with iASSESS Q&A! Learn moreCME
See all
CME
ROLE OF INTERVENTIONAL CARDIOLOGISTS IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES: REDEFINING CLINICAL PRACTICE This webcast will help interventional cardiologists and other members of the cardiac care team ensure that ASCVD patients receive optimal lipid-lowering therapy to reduce the risk of recurrent events.Expires
September 15, 2019
CME
TMVR: PREPARING FOR THE NEXT REVOLUTION 2019 This interactive program, led by expert faculty members, covers TMVR clinical trial design, appropriate patient selection and screening,and optimal care.
Expires
February 02, 2020
CME
UPDATES ON TAVR IN LOW-RISK PATIENTS This webcast discussion will move beyond high-risk patients and explore the new boundaries of transcatheter therapy. Participants will learn from discussions about considerations for low-risk patient populations, treatment decision making, and recent clinical trialdata.
Expires
December 25, 2019
CME
THE TREATMENT OF MITRAL REGURGITATION IN 2019 AND BEYOND This program will provide comprehensive overview of recent clinical trials and practical implications, case-based review of MR treatment options, and discussion of approaches for selecting appropriate surgical or transcatheter MR therapies.Expires
November 17, 2019
CME
TAVR IN 2019: APPROPRIATE METRICS FOR SUCCESS This webcast provides comprehensive discussion of TAVR as continued progress is seen in patients with low surgical risk. Emphasis is placed on approaches to integrating quality of life (QOL) metrics into pre-procedural planning, and utilizing scores for effective quantification of long-term outcomes in low-risk TAVR patients.Expires
November 07, 2019
CME
OPTIMIZING THE TAVR PATIENT PATHWAY This brief panel discussion touches upon expert-recommended approaches to such challenges- high case volume, patient education, care coordination- as well as other considerations for achieving excellence in heart team performance and patient outcomes in TAVR.Expires
October 25, 2019
CME
ROLE OF INTERVENTIONAL CARDIOLOGISTS IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES: REDEFINING CLINICAL PRACTICE This webcast will help interventional cardiologists and other members of the cardiac care team ensure that ASCVD patients receive optimal lipid-lowering therapy to reduce the risk of recurrent events.Expires
September 15, 2019
MEMBER CASES
Submit case See allCase
ROTABLATING THE UN-DIALATABLE LESIONSBy
Sai Satish, MD
Case
USING ONE CATHETER TREATS LAD CTO THROUGH SEPTAL BRANCH VIA TRANSRADIAL APPROACH, TIP INBy
Leisheng Ru
MOST POPULAR
1
OFF SCRIPT: THROUGH ‘PACLITAXELGATE,’ SOME UPSIDES TO UNCERTAINTY Off ScriptJuly 29, 20192
STRUCTURAL HEART HYPE: AS FELLOWSHIP PROGRAMS MUSHROOM, WHO’S KEEPING TABS ON QUALITY AND NUMBERS? FeatureAugust 2, 20193
TCTMD’S TOP 10 MOST POPULAR STORIES FOR JULY 2019 Daily NewsJuly 31, 20194
IS CHIP RELEVANT IN 2019? AND WHERE SHOULD INTERVENTIONAL CARDIOLOGY HEAD IN THE NEXT 5-10 YEARS? PresentationCHIP at ACC 2019March 15, 20195
STOPDAPT 2 – GLOBAL EXPERTS DISCUSS THE RESULTS AND IMPLICATIONS OF LANDMARK SHORT DAPT STUDY Topical DiscussionJune 6, 2019PARTNER EVENTS
ADVERTISEMENT
UPCOMING CONFERENCESSee all
TCT 2019
September 25
September 29, 2019
CONFERENCE COVERAGE
See all
TVT 2019
June 12
June 15, 2019
EUROPCR 2019
May 21
May 24, 2019
FELLOWS 2019
April 11
April 14, 2019
ADVERTISEMENT
BECOME A MEMBER
Register for TCTMD
Membership Plans
SIGN UP FOR OUR NEWSLETTER Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives. For more information, visit http://www.crf.org. Copyright © 2019. TCTMD All rights reserved.FOOTER
* About TCTMD
* Advertising & Sponsorships* Privacy Policy
* Editorial Policy
* Terms of Use
* FAQs
* Contact Us
Created by ConstructiveSIGN IN
New at TCTMD? Register today! Email Address PasswordForgot Password
FORGOT YOUR PASSWORD? Enter the email you used to register to reset your password.Email Address
SEARCH TCTMD
Search
Content Type Video Slides News Conference Member Cases Podcasts PagesManuscripts All
More Type Options All Topic Clinical Cardiology Coronary Endovascular Heart Failure Heart Rhythm Imaging Policy & Practice Structural Heart All Year 20192018201720162015201420132012All Conference Any ConferenceAll AATS AATS 2019AATS 2013All ACC ACC 2019ACC 2018ACC 2017ACC 2016ACC 2015ACC 2014ACC 2013ACC 2012ACC 2001All ACVS ACVS 2013ACVS 2012All AHA AHA 2018AHA 2017AHA 2016AHA 2015AHA 2014AHA 2013AHA 2012AHA 2011All ARCH ARCH 2019ARCH 2015Advances in Hemodynamic Support 2014Aortovascular 2015BIT 2019All BRS BRS 2015BRS 2014CADECI 2015CATCH-UP 2015All CCVVC CCVVC 2016CCVVC 2015All CDM CDM 2018CDM 2017All CHIP Florida CHIP Florida 2019CHIP Florida 2018CHIP Florida 2017CHIP Florida 2016CHIP Florida 2015All CHIP Seattle CHIP Seattle 2019CHIP Seattle 2018CHIP Seattle 2017CHIP Washington DC 2017All CHIP at ACC CHIP at ACC 2019CHIP at ACC 2018CICT 2015All CIT CIT 2019CIT 2018CIT 2014CIT 2013CIT 2012CRFTRAC 2017All CRT CRT 2019CRT 2018CRT 2017CRT 2016All CTO CTO 2019CTO 2018CTO 2017CTO 2016CTO 2015CTO 2014CTO 2013CTO 2012All Cardiovascular Interventions Cardiovascular Interventions 2019Cardiovascular Interventions 2018Cardiovascular Interventions 2017Cardiovascular Interventions 2016Cardiovascular Interventions 2014All Cell Therapy Cell Therapy 2014Cell Therapy 2013Cell Therapy 2012All Controversies and Advances Controversies and Advances 2018Controversies and Advances 2017All EAS EAS 2019EAS 2018EAS 2017EAS 2016All ECHO ECHO 2018ECHO 2017ECHO 2016ECHO 2015ECHO 2014ECHO 2013ECHO/IMAGING 2019EHRA 2019All ESC ESC 2018ESC 2017ESC 2016ESC 2015ESC 2014ESC 2013ESC 2012ESC 2011ESC Heart Failure 2019All EuroPCR EuroPCR 2019EuroPCR 2018EuroPCR 2017EuroPCR 2016EuroPCR 2015EuroPCR 2014EuroPCR 2013EuroPCR 2012EuroPCR 2011All Fellows Fellows 2019Fellows 2018Fellows 2017Fellows 2016Fellows 2015Fellows 2014Fellows 2013Fellows 2012GI2 2012All HRS HRS 2019HRS 2018All ICI ICI 2014ICI 2013ICI 2012All ISC ISC 2019ISC 2018ISC 2017ISC 2016All ISCTR ISCTR 2017ISCTR 2016All ISET ISET 2019ISET 2018ISET 2017ISET 2016ISET 2015ISET 2014ISET 2012All Intravascular Coronary Imaging and Physiology Intravascular Coronary Imaging and Physiology 2018Intravascular Coronary Imaging and Physiology 2016Intravascular Coronary Imaging and Physiology 2015All JIM JIM 2019JIM 2018JIM 2017JIM 2016All LAA LAA 2017LAA 2014All Miami Valves Miami Valves 2017Miami Valves 2016Miami Valves 2015Mitral Valve 2017OPCI 2019All PCI Outcomes PCI Outcomes 2014PCI Outcomes 2013PCI Outcomes 2012All PCR London Valves PCR London Valves 2018PCR London Valves 2017PCR London Valves 2016All Physiology and Intravascular Imaging Physiology and Intravascular Imaging 2018Physiology and Intravascular Imaging 2014SCAD 2018All SCAI SCAI 2019SCAI 2018SCAI 2017SCAI 2016SCAI 2013SCAI 2012SCAI 2011All SCCT SCCT 2019SCCT 2018SCCT 2017SCCT 2015SDCI 2015All SIF SIF 2019SIF 2017All SOLACI SOLACI 2017SOLACI 2016SOLACI 2013STS 2019SWVS 2017All Scripps Scripps 2016Scripps 2013All Stanford Coronary Physiology Conference Stanford Coronary Physiology Conference 2017Stanford Coronary Physiology Conference 2016Structural Heart and Imaging 2014All TCT TCT 2019TCT 2018TCT 2017TCT 2016TCT 2015TCT 2014TCT 2013TCT 2012TCT 2011TCT 2009TCT Abstracts Posters 2018TCT Mediterranean 2012All TCT Russia TCT Russia 2013TCT Russia 2012All TCTAP TCTAP 2018TCTAP 2013TCTAP 2012TEACH 2016All TTT TTT 2018TTT 2017All TVT TVT 2019TVT 2018TVT 2017TVT 2016TVT 2015TVT 2014TVT 2013TVT 2012The Structural Heart Disease Summit 2018Transradial 2013All VEINS VEINS 2014VEINS 2013VEINS 2012VEITH 2015All VIVA VIVA 2018VIVA 2017VIVA 2016WCC 2018All iASSESS iASSESS 2017iASSESS 2016iTOP 2019All Sort By relevancy By date ×By date Matching Exact phrase Include all of these words Include some of these words ×Include all of these wordscme
CME TITLE
First Name
Last Name
Degree Select a Degree MD DO PA PhD RN LPN NP Other Select a DegreeInstitution
If other, please specify ABIM Diplomate Number (Please provide if claiming MOC points)Address
Address 2 (Optional)City
State
Zip
Country Select a Country United States United Kingdom Australia Canada France New Zealand India Brazil Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Colombia Comoros Democratic Republic of the Congo Republic of the Congo Cook Islands Costa Rica Côte d'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Fiji Finland Gabon Gambia Georgia Germany Ghana Gibraltar Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Curacao Nicaragua Niger Nigeria Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Yemen Zambia Zimbabwe Select a Country Submit a Question for the Panel (Optional)MOBILE NAVIGATION
* " class="is-active">Home* News
* Conferences
* Cases
* Slides
* Videos
* Fellows Forum
* Cath Lab Forum
SUBMIT AN EVENT
Contact Email
Contact Phone NumberEvent Name
Location
Start Date
Start Time
End Date
End Time
Event Description
< >
BECOME A PREMIUM MEMBER OR LOG IN TO VIEW EXCLUSIVE CONTENT This content is available for meeting attendeesand/or Platinum Members REGISTER FOR FREE OR LOG IN TO VIEW THIS CONTENT Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and videoNow Playing
This website uses cookies to ensure you get the best experience on ourwebsite.
Read More
Got it
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0